List of Excipients in Branded Drug FOCALINXR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	FOCALINXR	dexmethylphenidate hydrochloride	54868-5681	DEXTROSE
Physicians Total Care Inc	FOCALINXR	dexmethylphenidate hydrochloride	54868-5681	FERRIC OXIDE YELLOW
Physicians Total Care Inc	FOCALINXR	dexmethylphenidate hydrochloride	54868-5681	GELATIN
Physicians Total Care Inc	FOCALINXR	dexmethylphenidate hydrochloride	54868-5681	POLYETHYLENE GLYCOL

Focalin XR Excipient Strategy and Commercial Opportunities

Last updated: October 23, 2026

Focalin XR is an extended-release capsule containing dexmethylphenidate hydrochloride, a Schedule II stimulant approved for attention-deficit/hyperactivity disorder. Its commercial value depends on multiparticulate release technology rather than the active ingredient alone. The capsule uses two populations of drug-loaded beads to provide an immediate-release fraction and a delayed-release fraction, producing a bimodal plasma-concentration profile over the day.[1]

The main commercial opportunities are generic or authorized-generic supply, pediatric sprinkle formulations, lower-cost capsule manufacturing, excipient redesign, abuse-resistance improvements, and differentiated products for patients who need predictable morning and afternoon coverage. The market is heavily exposed to generic competition, while formulation and manufacturing know-how remain relevant barriers.

What is Focalin XR and how does its release system work?

Focalin XR contains dexmethylphenidate hydrochloride, the d-enantiomer of methylphenidate. The product is available in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, and 40 mg extended-release capsules.[1]

The release profile is based on a 50:50 mixture of immediate-release and delayed-release drug-containing beads. The immediate-release beads produce early exposure. The delayed-release beads are designed to release drug later, creating a second exposure phase.[1]

Product characteristic	Focalin XR profile
Active ingredient	Dexmethylphenidate hydrochloride
Dosage form	Extended-release capsule
Administration	Oral; capsule may be swallowed or opened and sprinkled on applesauce
Release design	Immediate-release and delayed-release bead populations
Strengths	5 mg to 40 mg
Therapeutic category	CNS stimulant for ADHD
Regulatory pathway	NDA 021278
Controlled-substance status	Schedule II
Principal technical barrier	Reproducible multiparticulate release and bioequivalence

The formulation has two commercial implications. First, a generic cannot rely only on matching the total drug load. It must demonstrate appropriate pharmacokinetic performance across the full dosing interval. Second, the sprinkle capability creates a meaningful usability requirement for pediatric patients who cannot swallow capsules.

What excipients are used in Focalin XR?

The Focalin XR label identifies inactive ingredients associated with the bead system and capsule shell. The listed excipient classes include sugar spheres, hypromellose, ethylcellulose, povidone, talc, gelatin, titanium dioxide, and capsule colorants.[1]

Excipient or excipient class	Likely formulation role
Sugar spheres	Multiparticulate core or starter-pellet substrate
Hypromellose	Film former, binder, or release-controlling polymer
Ethylcellulose	Water-insoluble membrane for delayed release
Povidone	Binder and coating-process aid
Talc	Anti-tacking and processing aid in coating
Gelatin	Hard capsule shell
Titanium dioxide	Opacifier and pigment
FD&C colorants	Strength identification and product differentiation

The public label does not disclose every quantitative level or the complete manufacturing process. Those parameters are generally controlled by the product manufacturer and may be protected through manufacturing know-how, trade secrets, or formulation patents.

Why are sugar spheres important?

Sugar spheres allow the manufacturer to build drug layers and polymer membranes around a consistent starting particle. Particle-size distribution affects coating uniformity, drug loading, capsule fill weight, dissolution, and dose-to-dose variability.

A generic developer can substitute microcrystalline cellulose spheres or another starter core, but the substitution may alter:

• Pellet density and capsule fill volume
• Drug-layer adhesion
• Coating thickness
• Mechanical strength during processing
• Gastric and intestinal transit
• Dissolution behavior
• Sprinkle texture and mouthfeel

For a multiparticulate product, excipient substitution must be evaluated as a system. A change in the core material can require changes to binder concentration, coating weight gain, drying conditions, and capsule composition.

What is the role of ethylcellulose?

Ethylcellulose is a water-insoluble polymer commonly used to create a diffusion-controlled membrane. The delayed-release bead population can use ethylcellulose to restrict water penetration and drug diffusion. The membrane may also contain pore-forming components or other coating aids.

The commercial value of ethylcellulose is not its presence alone. The important parameters are polymer grade, viscosity, particle size, plasticization, coating weight, and membrane uniformity. Small process changes can shift the second release phase and create bioequivalence risk.

What is the role of hypromellose?

Hypromellose can function as a binder, film former, or hydrophilic release modifier. In a bead-based system, it may support drug-layer formation or contribute to release control. Its viscosity grade and concentration can materially affect aqueous penetration and drug release.

Hypromellose is also commercially attractive for generic developers because it is widely available, pharmacopeial, and compatible with aqueous or hydroalcoholic coating processes. Its broad availability reduces supply risk compared with specialized proprietary polymers.

What formulation patents protect Focalin XR?

Focalin XR protection has historically involved the dexmethylphenidate active ingredient, extended-release dosage-form technology, and product-specific regulatory exclusivity. The commercial product was approved under NDA 021278, and patent information was submitted to the FDA for Orange Book publication.[2]

The principal practical issue is that the original product’s major patent barriers have largely aged out relative to the product’s launch in 2001. Generic dexmethylphenidate extended-release capsules have been approved, indicating that the market is no longer protected by an effective product-wide monopoly.[3]

Protection category	Commercial relevance
Active-ingredient protection	Historically important; no longer the principal barrier
Multiparticulate release claims	Potentially relevant if unexpired claims remain in a particular jurisdiction
Method-of-use claims	May cover ADHD treatment but generally have limited blocking value against a fully labeled generic
Formulation claims	May affect specific bead architecture, coating composition, or release profile
Manufacturing claims	Can protect process parameters but are difficult to enforce without process evidence
Regulatory exclusivity	Historical importance; generic approvals demonstrate substantial erosion
Trade secrets	Current relevance for coating process, scale-up, and quality control

A patent review should separate claims directed to the active pharmaceutical ingredient from claims directed to the release architecture. A generic product may avoid a formulation patent by using a different polymer combination or a different bead process while still meeting the same pharmacokinetic target.

When did Focalin XR lose exclusivity?

Focalin XR has lost the commercial exclusivity associated with its original launch protection. The FDA has approved abbreviated new drug applications for dexmethylphenidate hydrochloride extended-release capsules, confirming that generic competition exists.[3]

Exclusivity issue	Assessment
Original NDA approval	2001
Current market structure	Brand plus multiple generic manufacturers
Brand-level market exclusivity	Expired or substantially eroded
Generic pathway	ANDA
Current competitive barrier	Bioequivalence, supply reliability, controlled-substance compliance, and contracting
Biosimilar pathway	Not applicable

Exact Orange Book patent status can change as listings expire, are delisted, or become legally irrelevant. The operative commercial fact is that generic products are approved and marketed.

What is the Orange Book status of Focalin XR?

Focalin XR is listed in FDA drug databases under NDA 021278. Its regulatory listing identifies the extended-release capsule dosage form and the approved strengths.[2]

The Orange Book matters for three reasons:

1. It identifies the reference listed drug for generic development.
2. It records patents submitted by the NDA holder.
3. It provides the regulatory framework for Paragraph IV certifications and generic approval timing.

Because generic dexmethylphenidate extended-release capsules have entered the market, Paragraph IV litigation is no longer the only relevant competitive event. The commercial analysis now focuses on active patents, generic launch status, market share, supply continuity, and payer substitution.

Which companies are challenging or competing with Focalin XR?

Competition comes primarily from generic manufacturers rather than biosimilar developers. Publicly documented generic applicants and suppliers have included large U.S. generic companies such as Teva and Actavis/Watson, with additional suppliers entering over time.[3]

Competitor type	Examples	Competitive mechanism
Brand reference product	Focalin XR	Physician recognition and established product profile
Generic extended-release capsules	Teva, Actavis/Watson and other ANDA holders	Lower price and formulary substitution
Immediate-release dexmethylphenidate	Generic Focalin tablets	Flexible titration but shorter duration
Methylphenidate extended-release products	Concerta, Ritalin LA, generic equivalents	Alternative release profiles and broader competition
Amphetamine stimulants	Adderall XR, lisdexamfetamine and generics	Therapeutic substitution
Nonstimulants	Atomoxetine, viloxazine, guanfacine	Different mechanism and controlled-substance profile

There is no biosimilar risk because dexmethylphenidate is a small molecule. The relevant threat is generic substitution and therapeutic switching.

What excipient strategies create commercial opportunities?

The most credible opportunities are incremental rather than revolutionary. A new product must improve a specific commercial attribute without losing the pharmacokinetic profile that defines the reference product.

1. Pediatric sprinkle optimization

Focalin XR can be opened and sprinkled on applesauce, but a developer can differentiate through:

• Reduced bead size
• Improved mouthfeel
• Lower grittiness
• Better adhesion to soft food
• More consistent dose recovery after sprinkling
• Packaging that simplifies caregiver administration
• Stability after capsule opening

Pediatric usability can support hospital, specialty-pharmacy, and caregiver adoption even where price competition is intense.

2. Excipient reduction

A simplified formulation may reduce exposure to colorants, titanium dioxide, gelatin, or specific processing aids. Potential markets include patients with excipient sensitivities, vegetarian or religious dietary requirements, and institutions with preferred formulary excipient policies.

A vegetarian capsule would require a substitute for gelatin, such as hypromellose. The change would affect moisture transmission, mechanical strength, capsule dissolution, and storage stability.

3. Modified capsule shells

Capsule-shell redesign can target:

• Vegetarian composition
• Lower moisture uptake
• Improved mechanical robustness
• Tamper visibility
• Color-free identification
• Child-resistant packaging compatibility

The shell is less likely than the bead system to determine bioequivalence, but it remains important for stability, patient acceptance, and manufacturing yield.

4. Polymer and coating-process optimization

Ethylcellulose and hypromellose are widely used, but process optimization can lower cost and reduce batch variability. Opportunities include:

• Aqueous rather than solvent-intensive coating
• Lower coating weight
• Improved fluid-bed utilization
• Reduced drying time
• Narrower pellet-size distribution
• Better in-process dissolution controls

These changes may improve gross margin without changing the labeled product concept.

5. Abuse-resistance development

Focalin XR is a Schedule II stimulant. A formulation with improved resistance to crushing, extraction, or rapid release could support a differentiated product strategy. Abuse-deterrent claims would require substantial technical evidence and FDA review. The product would also need to preserve the intended immediate-release and delayed-release exposure pattern.

Abuse-deterrence is commercially attractive but technically difficult. A harder capsule or polymer-coated bead does not automatically qualify as abuse-deterrent under FDA standards.[4]

What regulatory pathway applies to an improved Focalin XR product?

A conventional generic would normally use the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[5]

A materially redesigned product may require a different pathway:

Product concept	Likely pathway
Same active ingredient, same dosage form, equivalent release	ANDA
New excipient with equivalent performance	ANDA, subject to FDA review
New strength or dosing regimen	ANDA or 505(b)(2), depending on differences
New abuse-deterrent formulation	505(b)(2) or other FDA-supported pathway
New pediatric delivery system	Often 505(b)(2) if not fully substitutable
New therapeutic indication	505(b)(2) or supplemental NDA
New enantiomeric or molecular entity claim	Depends on regulatory history and exclusivity

For a generic developer, the commercial objective is to keep the formulation within the ANDA framework. A 505(b)(2) strategy may support stronger differentiation but adds clinical, regulatory, and labeling costs.

What manufacturing and intellectual-property barriers affect market entry?

The main barrier is reproducible manufacturing at commercial scale. A laboratory process that produces acceptable dissolution may fail during scale-up because bead coating is sensitive to airflow, spray rate, inlet temperature, atomization, and bed fluidization.

Important control points include:

• Starter-pellet size distribution
• Drug-layer uniformity
• Polymer coating weight gain
• Residual solvent or moisture
• Bead attrition
• Capsule fill-weight variation
• Dissolution at multiple time points
• Stability under high humidity
• Dose uniformity after sprinkling

Manufacturing know-how can remain commercially valuable after patents expire. A supplier with reliable controlled-substance sourcing, validated bead coating, and consistent dissolution performance may win contracts despite limited formal IP protection.

What generic launch risks exist for Focalin XR?

Generic launch risk is moderate to high because multiple approved products compete in a mature stimulant category. The main risks are commercial execution and supply, not the existence of a single blocking patent.

Risk	Effect on a new entrant
Multiple ANDA holders	Reduces attainable price and market share
Controlled-substance quotas	Can constrain supply
Active pharmaceutical ingredient shortages	Increases launch and continuity risk
Dissolution variability	Creates batch-release and recall exposure
Payer preference for incumbent generics	Raises contracting barriers
Pediatric administration issues	Can reduce adherence and substitution acceptance
Brand loyalty	Preserves some branded demand
Stimulant safety monitoring	Increases regulatory scrutiny

A new generic can improve its position through reliable supply, multiple strengths, retail availability, and a low-friction pharmacy substitution profile. A differentiated excipient system is more valuable when it solves a clear administration or tolerability problem.

How does Focalin XR compare with competing extended-release stimulants?

Focalin XR competes against products with different active ingredients and release technologies. Its main advantage is the dexmethylphenidate profile, which may be preferred for patients who respond to the d-enantiomer. Its main commercial weakness is that the therapeutic category has many substitutes.

Product category	Release approach	Excipient opportunity
Dexmethylphenidate ER	Multiparticulate, biphasic release	Sprinkle performance and bead-coating optimization
Methylphenidate ER tablets	Osmotic or matrix-based systems	Tablet swallowability and abuse resistance
Methylphenidate bead capsules	Multiparticulate release	Food-effect control and pediatric administration
Amphetamine ER capsules	Mixed bead or prodrug systems	Abuse deterrence and smooth exposure
Nonstimulants	Conventional oral dosage forms	Tolerability, once-daily dosing, and adherence

The strongest opportunity is not a simple “me-too” capsule. It is a product with a defensible patient-use advantage, a lower-cost manufacturing process, or a supply advantage in a shortage-prone controlled-substance market.

What is the revenue exposure and commercial outlook?

Focalin XR’s revenue exposure is structurally different from that of a newly launched protected medicine. Generic entry places pressure on price, while brand demand can persist through prescriptions written specifically for Focalin XR, pharmacy availability, and patient response.

Commercial value is concentrated in:

• High-dose strengths, particularly 20 mg to 40 mg
• Pediatric and adolescent prescribing
• Stable supply during generic shortages
• Specialty-pharmacy and Medicaid contracting
• Authorized-generic arrangements
• Reformulations with improved administration
• International markets with weaker generic penetration

A manufacturer should model revenue by strength, payer channel, generic substitution rate, controlled-substance quota, and supply reliability. Patent expiry alone is insufficient to forecast the remaining brand opportunity.

Key Takeaways

• Focalin XR uses dexmethylphenidate hydrochloride in a multiparticulate capsule with immediate-release and delayed-release bead populations.
• The core excipient system includes sugar spheres, hypromellose, ethylcellulose, povidone, talc, gelatin, titanium dioxide, and colorants.
• The principal technical barrier is reproducible bead coating and dissolution performance, not active-ingredient synthesis.
• Original exclusivity has been eroded by approved generic extended-release dexmethylphenidate products.
• Biosimilar risk is irrelevant because dexmethylphenidate is a small molecule.
• Commercial opportunities remain in pediatric sprinkle performance, vegetarian capsules, excipient reduction, manufacturing efficiency, abuse-resistance, and reliable controlled-substance supply.
• A conventional generic should favor the ANDA pathway. A substantially redesigned or abuse-deterrent product may require a 505(b)(2) strategy.
• The most defensible commercial advantage is a measurable patient, payer, or supply-chain benefit supported by a robust formulation and manufacturing package.

FAQs

Can Focalin XR be reformulated without changing the active ingredient?

Yes. A reformulation can change the capsule shell, coating polymer, starter core, colorants, or processing aids, provided the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and stability.

Which Focalin XR excipient is most important for delayed release?

Ethylcellulose is generally the most important membrane-forming excipient for diffusion-controlled delayed release. Its grade, coating level, and process conditions affect the timing and extent of drug release.

Is a vegetarian Focalin XR capsule commercially viable?

Yes. A hypromellose capsule can replace gelatin, but the developer must establish equivalent dissolution, moisture stability, mechanical performance, and product compatibility.

Can a generic Focalin XR product use different polymers?

Yes. A generic may use a different excipient composition if it achieves the required product quality and bioequivalence profile and complies with FDA requirements. The formulation change may also avoid claims directed to a particular polymer system.

Does Focalin XR have a biosimilar competitor?

No. Biosimilars apply to biologic products. Focalin XR contains the small-molecule active ingredient dexmethylphenidate hydrochloride and is subject to generic-drug competition.

References

1. U.S. Food and Drug Administration. (2023). Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules prescribing information. Novartis Pharmaceuticals Corporation.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Focalin XR, NDA 021278. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Electronic Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2015). Assessment of abuse deterrent properties of products intended for the treatment of pain: Guidance for industry. https://www.fda.gov/

5. U.S. Food and Drug Administration. (2013). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. https://www.fda.gov/